Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22526

Shown on this page

Current sort

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

MD Anderson Cancer Center

Live official records

Open in full search

Conditions: Synovial Sarcoma, Myxoid Liposarcoma
Interventions: afamitresgene autoleucel (previously ADP-A2M4); Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 10 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2038
U.S. locations: 17
States / cities: Duarte, California • Palo Alto, California • Aurora, Colorado + 13 more

Conditions: Symptomatic Venous Thromboembolism (VTE)
Interventions: REGN7508, Acetylsalicylic Acid (ASA), Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 42
States / cities: La Mesa, California • Rancho Mirage, California • Riverside, California + 32 more

Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more

Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions: Vaginal Fluid Collection, Blood Collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 21 more

Conditions: Obesity, Overweight, Osteoarthritis of the Knee
Interventions: Berobenatide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 39
States / cities: Tempe, Arizona • Escondido, California • Rancho Cucamonga, California + 30 more

Conditions: Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
Interventions: Bevacizumab, FOLFIRI, Pelareorep; Drug
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 20
States / cities: Homewood, Alabama • Beverly Hills, California • Encino, California + 16 more

Conditions: Atrial Fibrillation (AF)
Interventions: REGN7508, Apixaban, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 15,364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 56
States / cities: Alexander City, Alabama • Dothan, Alabama • Fairhope, Alabama + 50 more

Conditions: Cancer
Interventions: IDE574, Fulvestrant injection; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Santa Monica, California • New Haven, Connecticut • Plantation, Florida + 13 more

Conditions: Cutaneous Tumor, Malignant Solid Tumor
Interventions: JCXH-211; Drug
Lead sponsor: Immorna Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Biliary Cirrhosis
Interventions: Elafibranor 80mg, Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 46
States / cities: Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
Interventions: P-MUC1C-ALLO1 CAR-T cells, Rimiducid; Biological · Drug
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2039
U.S. locations: 14
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 11 more

Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions: PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer; Procedure · Radiation · Other + 1 more
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more

Clinical trials in Houston, Texas

Filter and sort this location

Institutions in Houston

Live official records

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer